Small Molecule CMO/CDMO Market Worth to Surpass US$ 102.01 Billion by 2030

The Small Molecule CMO/CDMO market is poised for substantial growth driven by increasing outsourcing trends in pharmaceutical manufacturing, rising demand for specialized contract services, and advancements in small molecule drug development

New York, Jan. 23, 2024 (GLOBE NEWSWIRE) — The global small molecule CMO/CDMO market is anticipated to grow at a 5.1% CAGR, reaching US$102.01 billion by 2030 from its 2023 value of US$72.01 billion.

Increasing pharmaceutical R&D investment, a rising demand for small molecules, and the growing prevalence of cancer and age-related disorders propel this market. The demand for cost-effective drugs, especially as small molecules are more economical than biological drugs, further supports market expansion.

Biotechnology CDMOs/CMOs offer a wide array of services, including development, packaging, clinical supply, analytical testing, biomanufacturing, and fill finishing. Collaboration with CDMOs by pharmaceutical, biopharma, and biotechnology firms for drug research and manufacturing outsourcing is a prevalent trend.

The production of biopharmaceuticals is influenced by manufacturing scale, where users can opt for the entire biologics production process for clinical or commercial purposes. The study focuses on clinical and commercial applications, measuring manufacturing capacity and revenue generated by biopharmaceutical contract manufacturing.

Elevate your business strategy with comprehensive market data. Request a sample report now:

Market Scope:

Report Coverage Details
Market Revenue 2023 US$ 72.01 Bn
Estimated Revenue 2030 US$ 1,02.01 Bn
Growth Rate – CAGR 5.1%  
Forecast Period 2023-2030
No. of Pages 157 Pages
Market Segmentation By Product, Service , Company Size, Scale of Operation and Region
Regions Covered North America, Latin America, Europe, South Asia & Pacific, East Asia, The Middle East & Africa
Key Companies Profiled
  • Pfizer CentreOne
  • Baxter BioPharma Solutions
  • Catalent
  • Lonza
  • Syngene International
  • Boehringer Ingelheim
  • Piramal Pharma Solutions
  • Wuxi AppTec

Small Molecule CMO/CDMO Market Analysis: 2019-2023 vs. 2024-2034 Forecast

From 2019 to 2023, the global small molecule CMO/CDMO market grew at a steady 3.8% CAGR, with projections suggesting further expansion at a 5.2% CAGR according to industry analysis.

Companies providing a broad spectrum of services, including drug substance manufacturing, drug product formulation, analytical services, and regulatory support, can act as a convenient one-stop shop for pharmaceutical firms. This simplifies outsourcing as clients can access all necessary expertise in one place, reducing the complexities of managing multiple vendors.

A significant advantage lies in the seamless integration of various drug development and manufacturing aspects. Firms with diverse portfolios can deliver integrated solutions, streamlining processes, minimizing communication gaps, and enhancing overall project efficiency.

Recognizing that pharmaceutical companies have varying needs at different drug development stages, CMOs and CDMOs with versatile service portfolios can adapt accordingly. This flexibility enables clients to maintain engagement with the same partner throughout the entire drug development lifecycle.

The involvement of multiple vendors for different aspects of drug development can intensify complexity. CMOs and CDMOs with comprehensive portfolios simplify this process, providing pharmaceutical companies with a single point of contact for a wide range of services.

In a nutshell, the Persistence Market Research report is a must-read for start-ups, industry players, investors, researchers, consultants, business strategists, and all those who are looking to understand this industry. Get a glance at the report at –

Market Dynamics:

Market Growth Factors

Rising Demand for Specialized Small Molecule Manufacturing Services

The Small Molecule CMO/CDMO market is growing because more pharmaceutical and biotech companies are outsourcing their small molecule drug development and production. They want CMO/CDMO partners with special skills. As drug development becomes more complicated, companies look for CMO/CDMOs with advanced technologies, specific knowledge, and a history of successful small molecule manufacturing. This creates a competitive environment where CMO/CDMOs keep expanding to meet the changing needs of the pharmaceutical industry.

Another reason for the Small Molecule CMO/CDMO market’s growth is the shift by pharmaceutical and biotech companies to outsource and save money. Outsourcing helps companies reduce costs, manage risks, and get the expertise of CMO/CDMO partners. This trend is especially noticeable in the small molecule segment, where complex manufacturing and strict quality requirements make collaboration with experienced CMO/CDMOs necessary.

Market Challenges

Regulatory Compliance Issues

A challenge for the Small Molecule CMO/CDMO market is dealing with complex regulatory requirements. The pharmaceutical industry operates under strict rules, and companies need to follow diverse and changing regulations to stay on top. CMO/CDMOs face the difficulty of meeting high-quality standards, dealing with different regional regulations, and adapting to new guidelines from health authorities. Failing to handle these challenges can lead to delays, increased costs, or regulatory problems, affecting a company’s dominance in the market.

Global Supply Chain Disruptions

The Small Molecule CMO/CDMO market faces a significant challenge with global supply chain disruptions. The interconnected nature of pharmaceutical supply chains exposes CMO/CDMOs to risks like shortages of raw materials, transportation issues, and geopolitical uncertainties. These disruptions can cause production delays, higher costs, and difficulties in meeting client demands. Overcoming these challenges requires smart risk management, flexible supply chain strategies, and proactive measures to ensure business continuity and resilience. Successfully managing global supply chain challenges is crucial for sustaining growth and competitiveness in the Small Molecule CMO/CDMO market.


Adopting Advanced Technologies for Growth

The Small Molecule CMO/CDMO Market has an opportunity to boost revenue by adopting cutting-edge technologies. Using advanced manufacturing technologies like continuous manufacturing, process analytical technology (PAT), and artificial intelligence can significantly improve efficiency, lower production costs, and simplify workflows. Small Molecule CMO/CDMOs that invest in these technologies can offer innovative and cost-effective solutions to pharmaceutical companies, attracting a broader client base and staying competitive in the market.

Market Segmentation

Increasing HPAPI Sales Driven by Demand for Specialized Therapies

The Small Molecule CMO/CDMO market is largely influenced by the demand for High Potency Active Pharmaceutical Ingredients (HPAPI). The growing need for specialized therapies, especially in oncology, has boosted the significance of HPAPI production. Due to their high potency and complex synthesis processes, precise manufacturing capabilities are required.

GMP Manufacturing Service Holds Highest Share Due to Real-time Data Monitoring Needs

The primary category in the Small Molecule CMO/CDMO market is GMP Manufacturing Service. Good Manufacturing Practice (GMP) is crucial for ensuring the quality and safety of pharmaceutical products during production. As companies outsource to specialized Contract Development and Manufacturing Organizations (CDMOs), the demand for GMP-compliant services has risen. Additionally, the fastest-growing category is Technology and Innovation services, meeting the demand for cutting-edge technologies and innovative solutions.

Large Companies Dominate with Extensive Resources

Large Companies take the lead in the Small Molecule CMO/CDMO market, holding a strong position in outsourcing due to their vast resources, diversified pipelines, and global operations. Collaboration with Contract Manufacturing Organizations (CMOs) and Contract Development and Manufacturing Organizations (CDMOs) allows them to leverage specialized expertise and capacity. The fastest-growing category is Mid-sized Companies, catering to emerging pharmaceutical and biotech firms with flexible, specialized services, and a collaborative approach.

Country-wise Insights

United States: The U.S. leads in North America’s small molecule CMO/CDMO market due to a growing pharmaceutical sector. The market is projected to reach US$ 23,495.7 million by 2030, with a 4.8% CAGR. U.S.-based CMOs/CDMOs are expanding globally, and technological advancements attract outsourcing opportunities.

China: China’s small molecule CMO/CDMO market is expected to grow at a 6.5% CAGR, reaching US$ 37,932.6 million by 2030. The rise is driven by increasing pharmaceutical demand, regulatory reforms, and strategic alliances with international businesses.

Germany: Germany’s small molecule CMO/CDMO market is forecasted to reach US$ 5,308.6 million by 2030, with a 3.9% CAGR. Germany’s strict quality standards, advanced research facilities, and regulatory compliance make it an attractive hub for reliable manufacturing partners.

Japan: Japan’s small molecule CMO/CDMO market is set to grow at a 5.2% CAGR, reaching US$ 22,989.8 million by 2030. The growth is fueled by Japan-based pharmaceutical companies focusing on cost reduction and expanding the generic drug sector. Adoption of manufacturing services by leading companies contributes to market growth.

Competitive Intelligence and Business Strategy

Leading companies like Pfizer CentreOne, Baxter BioPharma Solutions, Catalent, and Lonza are at the forefront of the pharmaceutical outsourcing sector. Competitive intelligence plays a crucial role in shaping business strategies for these organizations. Companies closely examine their competitors’ capabilities, technological advancements, and services. This insight helps identify market gaps, understand pricing trends, and gauge customer preferences. Successful players use competitive intelligence to improve their services, enhance operational efficiency, and comply with changing regulations. The ability to predict market trends and competitors’ actions allows firms to stay flexible, encourage innovation, and maintain a strategic advantage in a rapidly evolving industry.

In the Small Molecule CMO/CDMO market, achieving lasting success requires a multifaceted approach. Proactive business strategies involve forming strategic partnerships with pharmaceutical companies, diversifying service offerings, and investing in advanced technologies. To gain a competitive edge, companies focus on operational excellence, ensuring a smooth transition from development to manufacturing. Additionally, fostering a culture of innovation and continuous improvement is crucial for sustained success.

Key Questions Answered in the Report:

  1. What are the contributing factors to the market’s growth trends?
  2. What is the current market size, and how is it expected to change in the upcoming years?
  3. What are the key elements exerting influence on the market?
  4. How is the Small Molecule CMO/CDMO market segmented, considering types, applications, fuels, or other relevant factors?
  5. Who are the major participants in the Small Molecule CMO/CDMO market?
  6. What strategies are these players employing to establish a competitive edge?
  7. What factors are propelling the expansion of the Small Molecule CMO/CDMO market?
  8. Which regions are anticipated to witness notable growth, and what are the driving factors behind it?
  9. What recent technological advancements are impacting the Small Molecule CMO/CDMO industry?

About Persistence Market Research:

Business intelligence is the foundation of every business model employed by Persistence Market Research. Multi-dimensional sources are being put to work, which include big data, customer experience analytics, and real-time data collection. Thus, working on “micros” by Persistence Market Research helps companies overcome their “macro” business challenges.

Persistence Market Research is always way ahead of its time. In other words, it tables market solutions by stepping into the companies’/clients’ shoes much before they themselves have a sneak pick into the market. The pro-active approach followed by experts at Persistence Market Research helps companies/clients lay their hands on techno-commercial insights beforehand, so that the subsequent course of action could be simplified on their part.


Persistence Market Research

Teerth Technospace, Unit B-704

Survey Number – 103, Baner

Mumbai Bangalore Highway

Pune 411045 India

Email: [email protected]


Originally published at